Zelgen Biopharmaceuticals has developed strong capabilities in research, development, manufacturing and commercialization of innovative products, and has built a robust pipeline of potential BIC/FIC products in the fields of oncology, bleeding and heamatologic disorders, immuno-inflammatory diseases and hepatobiliary diseases. To accelerate the clinical development and commercialization of our innovative product pipeline, and maximize the clinical and commercial value, we have been actively exploring value-added strategic partnerships, including but not limited to product licensing, co-development and collaboration in China and worldwide. 

 If you are interested in collaborating with us, please contact: BD@ahacm.com.